Switch theme
Sign up to access all valuation multiples
Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group’s product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.
2013
164
LTM Revenue $1.2M
LTM EBITDA -$22.1M
$506M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Luzhu Biotech has a last 12-month revenue (LTM) of $1.2M and a last 12-month EBITDA of -$22.1M.
In the most recent fiscal year, Luzhu Biotech achieved revenue of n/a and an EBITDA of -$18.2M.
Luzhu Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Luzhu Biotech valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $1.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$22.1M | XXX | -$18.2M | XXX | XXX | XXX |
| EBITDA Margin | -1889% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$25.2M | XXX | -$23.4M | XXX | XXX | XXX |
| EBIT Margin | -2155% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$25.7M | XXX | -$21.5M | XXX | XXX | XXX |
| Net Margin | -2199% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Luzhu Biotech's stock price is HKD 22 (or $3).
Luzhu Biotech has current market cap of HKD 4.4B (or $559M), and EV of HKD 4.0B (or $506M).
See Luzhu Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $506M | $559M | XXX | XXX | XXX | XXX | $-0.12 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Luzhu Biotech has market cap of $559M and EV of $506M.
Luzhu Biotech's trades at n/a EV/Revenue multiple, and -27.8x EV/EBITDA.
Equity research analysts estimate Luzhu Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Luzhu Biotech has a P/E ratio of -23.6x.
See valuation multiples for Luzhu Biotech and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $559M | XXX | $559M | XXX | XXX | XXX |
| EV (current) | $506M | XXX | $506M | XXX | XXX | XXX |
| EV/Revenue | 469.9x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -24.9x | XXX | -27.8x | XXX | XXX | XXX |
| EV/EBIT | -21.8x | XXX | -21.6x | XXX | XXX | XXX |
| EV/Gross Profit | 490.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -23.6x | XXX | -26.1x | XXX | XXX | XXX |
| EV/FCF | -17.6x | XXX | -21.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLuzhu Biotech's last 12 month revenue growth is 2370%
Luzhu Biotech's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.1M for the same period.
Luzhu Biotech's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Luzhu Biotech's rule of X is 4036% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Luzhu Biotech and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2370% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -1889% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -75% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 4036% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Luzhu Biotech acquired XXX companies to date.
Last acquisition by Luzhu Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Luzhu Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Luzhu Biotech founded? | Luzhu Biotech was founded in 2013. |
| Where is Luzhu Biotech headquartered? | Luzhu Biotech is headquartered in Hong Kong. |
| How many employees does Luzhu Biotech have? | As of today, Luzhu Biotech has 164 employees. |
| Is Luzhu Biotech publicy listed? | Yes, Luzhu Biotech is a public company listed on HKG. |
| What is the stock symbol of Luzhu Biotech? | Luzhu Biotech trades under 02480 ticker. |
| When did Luzhu Biotech go public? | Luzhu Biotech went public in 2023. |
| Who are competitors of Luzhu Biotech? | Similar companies to Luzhu Biotech include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Luzhu Biotech? | Luzhu Biotech's current market cap is $559M |
| What is the current revenue of Luzhu Biotech? | Luzhu Biotech's last 12 months revenue is $1.2M. |
| What is the current revenue growth of Luzhu Biotech? | Luzhu Biotech revenue growth (NTM/LTM) is 2370%. |
| What is the current EV/Revenue multiple of Luzhu Biotech? | Current revenue multiple of Luzhu Biotech is 469.9x. |
| Is Luzhu Biotech profitable? | Yes, Luzhu Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Luzhu Biotech? | Luzhu Biotech's last 12 months EBITDA is -$22.1M. |
| What is Luzhu Biotech's EBITDA margin? | Luzhu Biotech's last 12 months EBITDA margin is -1889%. |
| What is the current EV/EBITDA multiple of Luzhu Biotech? | Current EBITDA multiple of Luzhu Biotech is -24.9x. |
| What is the current FCF of Luzhu Biotech? | Luzhu Biotech's last 12 months FCF is -$31.2M. |
| What is Luzhu Biotech's FCF margin? | Luzhu Biotech's last 12 months FCF margin is -2663%. |
| What is the current EV/FCF multiple of Luzhu Biotech? | Current FCF multiple of Luzhu Biotech is -17.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
